Literature DB >> 26631239

Selective internal radiation therapy in patients with progressive neuroendocrine liver metastases.

Charlotte Ebeling Barbier1, Ulrike Garske-Román2, Mattias Sandström2, Rickard Nyman3, Dan Granberg4.   

Abstract

PURPOSE: To evaluate the safety and efficacy of selective internal radiation therapy (SIRT) in patients with unresectable liver metastases from neuroendocrine tumours (NETLMs).
METHODS: This retrospective study included 40 patients with progressive NETLMs (22 women, 18 men, mean age 61.6 years) who underwent SIRT with (90)Y-labelled resin microspheres. Tumour response was evaluated according to the modified Response Evaluation Criteria in Solid Tumors (mRECIST) on CT or MR images. Medical records were reviewed.
RESULTS: In the 40 patients, 54 evaluable SIRT procedures were performed, 33 to the right liver lobe (mean activity 1.31 GBq), 13 to the left lobe (mean activity 0.85 GBq), and 8 to both lobes (mean activity 1.61 GBq). Late follow-up imaging (mean 20 months) was performed after 44 of the treatments. Objective tumour response and disease control rates were 54 % (29 of 54 treatments) and 94 % (51 treatments), respectively, at the early follow-up examination (mean 3 months) and 34 % (15 treatments) and 57 % (25 treatments), respectively at the late follow-up examination. Mean overall survival from the first SIRT was 34,8 months and survival rates at 1, 2, 3 and 5 years were 76 %, 59 %, 52 % and 35 % respectively. Adverse effects were generally mild and easily manageable, except in one patient who died from radiation-induced liver failure. Of the 45 patients, 18 (45 %) had received peptide receptor radionuclide therapy (PRRT) prior to SIRT.
CONCLUSION: SIRT with (90)Y-labelled resin microspheres is a safe and effective treatment for patients with progressive NETLM, and also for those who have received prior PRRT.

Entities:  

Keywords:  Neuroendocrine liver metastases; Selective internal radiation therapy; Transarterial; Yttrium

Mesh:

Year:  2015        PMID: 26631239     DOI: 10.1007/s00259-015-3264-6

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  34 in total

1.  Hepatic arterial chemoembolization in the management of advanced digestive endocrine tumors.

Authors:  P Ruszniewski; D Malka
Journal:  Digestion       Date:  2000       Impact factor: 3.216

2.  Radioembolization for treatment of liver metastases from neuroendocrine tumors: correlation with imaging and biomarkers.

Authors:  Junko Ozao-Choy; Marc L Friedman; Amanda S Kim; Ashely Wachsman; Edward M Wolin; Run Yu; Nicholas N Nissen; Steven D Colquhoun
Journal:  Pancreas       Date:  2013-03       Impact factor: 3.327

3.  Factors predicting response and survival after yttrium-90 radioembolization of unresectable neuroendocrine tumor liver metastases: a critical appraisal of 48 cases.

Authors:  Akshat Saxena; Terence C Chua; Lourens Bester; Adel Kokandi; David L Morris
Journal:  Ann Surg       Date:  2010-05       Impact factor: 12.969

4.  Radioembolization for neuroendocrine liver metastases: safety, imaging, and long-term outcomes.

Authors:  Khairuddin Memon; Robert J Lewandowski; Mary F Mulcahy; Ahsun Riaz; Robert K Ryu; Kent T Sato; Ramona Gupta; Paul Nikolaidis; Frank H Miller; Vahid Yaghmai; Vanessa L Gates; Bassel Atassi; Steven Newman; Reed A Omary; Al B Benson; Riad Salem
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-12-02       Impact factor: 7.038

Review 5.  Modified RECIST (mRECIST) assessment for hepatocellular carcinoma.

Authors:  Riccardo Lencioni; Josep M Llovet
Journal:  Semin Liver Dis       Date:  2010-02-19       Impact factor: 6.115

6.  Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma.

Authors:  Frank T Kolligs; Jose I Bilbao; Tobias Jakobs; Mercedes Iñarrairaegui; Jutta M Nagel; Macarena Rodriguez; Alexander Haug; Delia D'Avola; Mark op den Winkel; Antonio Martinez-Cuesta; Christoph Trumm; Alberto Benito; Klaus Tatsch; Christoph J Zech; Ralf-Thorsten Hoffmann; Bruno Sangro
Journal:  Liver Int       Date:  2015-01-17       Impact factor: 5.828

7.  Radioembolization of symptomatic, unresectable neuroendocrine hepatic metastases using yttrium-90 microspheres.

Authors:  Philipp M Paprottka; Ralf-T Hoffmann; Alexander Haug; Wieland H Sommer; Franziska Raessler; Christoph G Trumm; Gerwin P Schmidt; Nima Ashoori; Maximilian F Reiser; Tobias F Jakobs
Journal:  Cardiovasc Intervent Radiol       Date:  2011-08-17       Impact factor: 2.740

8.  Liver metastases of neuroendocrine tumors: treatment with hepatic transarterial chemotherapy using two therapeutic protocols.

Authors:  Thomas J Vogl; Tatjana Gruber; Nagy N N Naguib; Renate Hammerstingl; Nour-Eldin A Nour-Eldin
Journal:  AJR Am J Roentgenol       Date:  2009-10       Impact factor: 3.959

9.  Hepatic artery chemoinfusion with chemoembolization for neuroendocrine cancer with progressive hepatic metastases despite octreotide therapy.

Authors:  Dara Christante; Suellen Pommier; Babak Givi; Rodney Pommier
Journal:  Surgery       Date:  2008-12       Impact factor: 3.982

10.  Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients.

Authors:  Andrew S Kennedy; William A Dezarn; Patrick McNeillie; Doug Coldwell; Charles Nutting; Dennis Carter; Ravi Murthy; Steven Rose; Richard R P Warner; David Liu; Holger Palmedo; Carroll Overton; Bonita Jones; Riad Salem
Journal:  Am J Clin Oncol       Date:  2008-06       Impact factor: 2.339

View more
  14 in total

Review 1.  Treatment Strategies for Metastatic Neuroendocrine Tumors of the Gastrointestinal Tract.

Authors:  Mauro Cives; Jonathan Strosberg
Journal:  Curr Treat Options Oncol       Date:  2017-03

Review 2.  Radioembolization in the Setting of Systemic Therapies.

Authors:  Tarub S Mabud; Ryan Hickey
Journal:  Semin Intervent Radiol       Date:  2021-10-07       Impact factor: 1.780

Review 3.  Safety of selective internal radiation therapy (SIRT) with yttrium-90 microspheres combined with systemic anticancer agents: expert consensus.

Authors:  Andrew Kennedy; Daniel B Brown; Jonas Feilchenfeldt; John Marshall; Harpreet Wasan; Marwan Fakih; Peter Gibbs; Alexander Knuth; Bruno Sangro; Michael C Soulen; Gianfranco Pittari; Ricky A Sharma
Journal:  J Gastrointest Oncol       Date:  2017-12

4.  Clinical Application of Radioembolization in Hepatic Malignancies: Protocol for a Prospective Multicenter Observational Study.

Authors:  Thomas Helmberger; Dirk Arnold; José I Bilbao; Niels de Jong; Geert Maleux; Anders Nordlund; Bora Peynircioglu; Bruno Sangro; Ricky A Sharma; Agnes Walk
Journal:  JMIR Res Protoc       Date:  2020-04-22

Review 5.  Current and emerging therapies for PNETs in patients with or without MEN1.

Authors:  Morten Frost; Kate E Lines; Rajesh V Thakker
Journal:  Nat Rev Endocrinol       Date:  2018-02-16       Impact factor: 43.330

Review 6.  Liver-Directed Therapies for Neuroendocrine Neoplasms.

Authors:  Ashley Kieran Clift; Andrea Frilling
Journal:  Curr Oncol Rep       Date:  2021-03-15       Impact factor: 5.075

7.  Radioembolization Versus Bland Embolization for Hepatic Metastases from Small Intestinal Neuroendocrine Tumors: Short-Term Results of a Randomized Clinical Trial.

Authors:  Anna-Karin Elf; Mats Andersson; Olof Henrikson; Oscar Jalnefjord; Maria Ljungberg; Johanna Svensson; Bo Wängberg; Viktor Johanson
Journal:  World J Surg       Date:  2018-02       Impact factor: 3.352

Review 8.  Molecular imaging reporting and data systems (MI-RADS): a generalizable framework for targeted radiotracers with theranostic implications.

Authors:  Rudolf A Werner; Ralph A Bundschuh; Lena Bundschuh; Mehrbod S Javadi; Takahiro Higuchi; Alexander Weich; Sara Sheikhbahaei; Kenneth J Pienta; Andreas K Buck; Martin G Pomper; Michael A Gorin; Constantin Lapa; Steven P Rowe
Journal:  Ann Nucl Med       Date:  2018-08-14       Impact factor: 2.668

9.  Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver (RETNET): study protocol for a randomized controlled trial.

Authors:  James X Chen; E Paul Wileyto; Michael C Soulen
Journal:  Trials       Date:  2018-07-17       Impact factor: 2.279

10.  Clinical Application of Trans-Arterial Radioembolization in Hepatic Malignancies in Europe: First Results from the Prospective Multicentre Observational Study CIRSE Registry for SIR-Spheres Therapy (CIRT).

Authors:  Thomas Helmberger; Rita Golfieri; Maciej Pech; Thomas Pfammatter; Dirk Arnold; Roberto Cianni; Geert Maleux; Graham Munneke; Olivier Pellerin; Bora Peynircioglu; Bruno Sangro; Niklaus Schaefer; Niels de Jong; José Ignacio Bilbao
Journal:  Cardiovasc Intervent Radiol       Date:  2020-09-21       Impact factor: 2.740

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.